Eleven Biotherapeutics raises $50M in IPO

Eleven Biotherapeutics' (EBIO) shares are due to begin trading on Nasdaq today after the company raised $50M in an IPO by selling 5M shares at $10 each. That's below the initial range of $13-15, although Eleven Biotherapeutics was expected to sell only 4.3M shares.

There's also a greenshoe option for another 750,000 shares.

Eleven Biotherapeutics develops treatments for eye diseases using its proprietary protein-engineering platform, AMP-Rx.

The firm's lead candidate is EBI-005, which its developing as a topical treatment for dry eye disease and allergic conjunctivitis. (PR)

Seeking Alpha previews: Don Dion; IPOdesktop


Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs